01/18/2021 | Press release | Distributed by Public on 01/18/2021 12:19
Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Treatment for Sickle Cell Disease, for Pivotal Trial
Lonza to perform process development activities to establish a robust manufacturing process for ARU-1801, a potentially curative treatment for sickle cell disease
Lonza to provide cGMP material supply of ARU-1801 for its use in a pivotal clinical study in the United States
Quote from Palani Palaniappan, Chief Technology Officer, Aruvant Sciences: We are partnering with Lonza, one of the world s leading cell and gene therapy manufacturing organizations, to help us manufacture our gene therapy, ARU-1801, a potential cure for sickle cell disease that can be given with one low dose of chemotherapy. Our internal cell therapy process expertise combined with Lonza s cell processing know-how provide the perfect combination to manufacture ARU-1801 for our pivotal study. As we advanceour gene ther